![Novartis Piqray® – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval[1]](https://bmglobalnews.com/wp-content/uploads/https://www.media-outreach.com/Release/templates/images/socialMedia/iconmonstr-twitter-1-24.png){kind=small}
Novartis Piqray® – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval[1]
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation The approval was based on SOLAR-1 Phase ...